首页 > 最新文献

Human Vaccines & Immunotherapeutics最新文献

英文 中文
Research trends of neoadjuvant therapy for breast cancer: A bibliometric analysis.
IF 4.1 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Pub Date : 2025-12-01 Epub Date: 2025-02-04 DOI: 10.1080/21645515.2025.2460272
Laiping Xie, Yuhang Wang, Andi Wan, Lin Huang, Qing Wang, Wanyan Tang, Xiaowei Qi, Xiaofei Hu

The approach of neoadjuvant therapy for breast cancer, which involves administering systemic treatment prior to primary surgery, has undergone substantial advancements in recent decades. This strategy is intended to reduce tumor size, thereby enabling less invasive surgical procedures and enhancing patient outcomes. This study presents a comprehensive bibliometric analysis of research trends in neoadjuvant therapy for breast cancer from 2009 to 2024. Using data extracted from the Web of Science Core Collection, a total of 3,674 articles were analyzed to map the research landscape in this field. The analysis reveals a steady increase in publication output, peaking in 2022, with the United States and China identified as the leading contributors. Key institutions, such as the University of Texas System and MD Anderson Cancer Center, have been instrumental in advancing the research on neoadjuvant therapy. The study also highlights the contributions of influential authors like Sibylle Loibl and Gunter von Minckwitz, as well as major journals such as the Journal of Clinical Oncology. Emerging research topics, including immunotherapy, liquid biopsy, and artificial intelligence, are gaining prominence and represent potential future directions for clinical applications. This bibliometric analysis provides critical insights into global research trends, key contributors, and future developments in the field of neoadjuvant therapy for breast cancer, offering a foundation for future research and clinical practice advancements.

{"title":"Research trends of neoadjuvant therapy for breast cancer: A bibliometric analysis.","authors":"Laiping Xie, Yuhang Wang, Andi Wan, Lin Huang, Qing Wang, Wanyan Tang, Xiaowei Qi, Xiaofei Hu","doi":"10.1080/21645515.2025.2460272","DOIUrl":"10.1080/21645515.2025.2460272","url":null,"abstract":"<p><p>The approach of neoadjuvant therapy for breast cancer, which involves administering systemic treatment prior to primary surgery, has undergone substantial advancements in recent decades. This strategy is intended to reduce tumor size, thereby enabling less invasive surgical procedures and enhancing patient outcomes. This study presents a comprehensive bibliometric analysis of research trends in neoadjuvant therapy for breast cancer from 2009 to 2024. Using data extracted from the Web of Science Core Collection, a total of 3,674 articles were analyzed to map the research landscape in this field. The analysis reveals a steady increase in publication output, peaking in 2022, with the United States and China identified as the leading contributors. Key institutions, such as the University of Texas System and MD Anderson Cancer Center, have been instrumental in advancing the research on neoadjuvant therapy. The study also highlights the contributions of influential authors like Sibylle Loibl and Gunter von Minckwitz, as well as major journals such as the Journal of Clinical Oncology. Emerging research topics, including immunotherapy, liquid biopsy, and artificial intelligence, are gaining prominence and represent potential future directions for clinical applications. This bibliometric analysis provides critical insights into global research trends, key contributors, and future developments in the field of neoadjuvant therapy for breast cancer, offering a foundation for future research and clinical practice advancements.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2460272"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11801352/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143190984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of a multimedia campaign to increase human papillomavirus vaccine acceptance in Dhaka, Bangladesh. 孟加拉国达卡为提高人乳头瘤病毒疫苗接受度而开展的多媒体宣传活动的效果。
IF 4.1 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Pub Date : 2025-12-01 Epub Date: 2025-01-08 DOI: 10.1080/21645515.2024.2447105
Sohail Agha, Sarah Francis, Drew Bernard, Aslam Fareed, Kasrina Azad, Firdausi Qadri

Increasing the uptake of Human Papillomavirus (HPV) vaccine among adolescent girls is a high priority for the government of Bangladesh. This study examines correlates of HPV vaccine adoption in Dhaka Division, the largest division in Bangladesh. The 18-day vaccination campaign was accompanied by multimedia messages. We use the Fogg Behavior Model (FBM) as the theoretical framework for our analysis. Using a survey instrument based on the FBM, we analyze cross-sectional data collected from 611 caregivers of girls aged 9-17 in Dhaka. Survey data was collected in November and December 2023. Caregivers were recruited via Facebook and Instagram ads and interviewed through the Facebook Messenger App. About one-third of caregivers reported that their child had been vaccinated. We conducted bivariate and multivariate analyses to assess the relationships between the caregivers' motivation, ability, exposure to the campaign and their child's vaccination status. Adjusted odds ratios from logistic regression analyses, suggest that caregivers' motivation, ability, and exposure to the multimedia campaign contributed to vaccine uptake. Caregivers' motivation to get their child vaccinated was high (74%) but their ability was low (20%). Exposure to campaign messages had a dose-response relationship with vaccine adoption. However, 48% of caregivers remained unexposed to the multimedia campaign. We discuss challenges that the government's HPV vaccination program is likely to face and identify program-related research questions that are important to answer for the success of future vaccination efforts.

在青春期女孩中增加人乳头瘤病毒(HPV)疫苗的吸收是孟加拉国政府的高度优先事项。本研究调查了孟加拉国最大的地区达卡地区HPV疫苗采用的相关因素。为期18天的疫苗接种活动伴随着多媒体信息。我们使用Fogg行为模型(FBM)作为我们分析的理论框架。使用基于FBM的调查工具,我们分析了从达卡611名9-17岁女孩的照顾者中收集的横断面数据。调查数据于2023年11月和12月收集。护理人员通过Facebook和Instagram广告招募,并通过Facebook Messenger应用程序进行采访。大约三分之一的护理人员报告说,他们的孩子已经接种了疫苗。我们进行了双变量和多变量分析,以评估照顾者的动机、能力、对运动的接触与孩子的疫苗接种状况之间的关系。从逻辑回归分析中调整的优势比表明,护理人员的动机、能力和对多媒体活动的接触有助于疫苗的吸收。照顾者让孩子接种疫苗的动机很高(74%),但他们的能力很低(20%)。接触运动信息与接种疫苗有剂量-反应关系。然而,48%的护理人员仍然没有接触到多媒体活动。我们讨论了政府的HPV疫苗接种计划可能面临的挑战,并确定了与计划相关的研究问题,这些问题对未来疫苗接种工作的成功至关重要。
{"title":"Effects of a multimedia campaign to increase human papillomavirus vaccine acceptance in Dhaka, Bangladesh.","authors":"Sohail Agha, Sarah Francis, Drew Bernard, Aslam Fareed, Kasrina Azad, Firdausi Qadri","doi":"10.1080/21645515.2024.2447105","DOIUrl":"10.1080/21645515.2024.2447105","url":null,"abstract":"<p><p>Increasing the uptake of Human Papillomavirus (HPV) vaccine among adolescent girls is a high priority for the government of Bangladesh. This study examines correlates of HPV vaccine adoption in Dhaka Division, the largest division in Bangladesh. The 18-day vaccination campaign was accompanied by multimedia messages. We use the Fogg Behavior Model (FBM) as the theoretical framework for our analysis. Using a survey instrument based on the FBM, we analyze cross-sectional data collected from 611 caregivers of girls aged 9-17 in Dhaka. Survey data was collected in November and December 2023. Caregivers were recruited via Facebook and Instagram ads and interviewed through the Facebook Messenger App. About one-third of caregivers reported that their child had been vaccinated. We conducted bivariate and multivariate analyses to assess the relationships between the caregivers' motivation, ability, exposure to the campaign and their child's vaccination status. Adjusted odds ratios from logistic regression analyses, suggest that caregivers' motivation, ability, and exposure to the multimedia campaign contributed to vaccine uptake. Caregivers' motivation to get their child vaccinated was high (74%) but their ability was low (20%). Exposure to campaign messages had a dose-response relationship with vaccine adoption. However, 48% of caregivers remained unexposed to the multimedia campaign. We discuss challenges that the government's HPV vaccination program is likely to face and identify program-related research questions that are important to answer for the success of future vaccination efforts.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2447105"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11730613/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142957495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Willingness to pay for vaccines in China: A systematic review and single-arm Bayesian meta-analysis.
IF 4.1 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Pub Date : 2025-12-01 Epub Date: 2025-02-04 DOI: 10.1080/21645515.2025.2454076
Yi Li, Ziwei Liu, Liangru Zhou, Ruifeng Li

The effective implementation of vaccination heavily depends on the society's willingness to pay (WTP). There is currently a dearth of comprehensive evidence about WTP for vaccines in China. This systematic review aims to review studies on the WTP for vaccines, to summarize factors affect WTP in China. Base-case analysis and Sensitivity analysis of WTP for every vaccine were estimated via single-arm Bayesian meta-analysis. A total of 28 studies were included for systematic review. The point estimates and 95% Credible Interval of pooled WTP for influenza and HPV (9-valent) vaccine were $27.409 (23.230, 31.486), $464.707 (441.355, 489.456). Influencing factors to WTP were age, income, peer influence, health condition and etc. Future research should give focus to improving sample representativeness and survey tool, conducting intervention trials, identifying effective methods to promote WTP.

{"title":"Willingness to pay for vaccines in China: A systematic review and single-arm Bayesian meta-analysis.","authors":"Yi Li, Ziwei Liu, Liangru Zhou, Ruifeng Li","doi":"10.1080/21645515.2025.2454076","DOIUrl":"10.1080/21645515.2025.2454076","url":null,"abstract":"<p><p>The effective implementation of vaccination heavily depends on the society's willingness to pay (WTP). There is currently a dearth of comprehensive evidence about WTP for vaccines in China. This systematic review aims to review studies on the WTP for vaccines, to summarize factors affect WTP in China. Base-case analysis and Sensitivity analysis of WTP for every vaccine were estimated via single-arm Bayesian meta-analysis. A total of 28 studies were included for systematic review. The point estimates and 95% Credible Interval of pooled WTP for influenza and HPV (9-valent) vaccine were $27.409 (23.230, 31.486), $464.707 (441.355, 489.456). Influencing factors to WTP were age, income, peer influence, health condition and etc. Future research should give focus to improving sample representativeness and survey tool, conducting intervention trials, identifying effective methods to promote WTP.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2454076"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11796539/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143190986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
"The big topic is COVID": A qualitative study about changes in HPV vaccine conversations between parents and primary care team members throughout the COVID-19 pandemic.
IF 4.1 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Pub Date : 2025-12-01 Epub Date: 2025-02-06 DOI: 10.1080/21645515.2025.2460844
Josheili Y Llavona-Ortiz, Lauren J Van Scoy, Benjamin Fogel, Casey Pinto, Jamelia Graham, William A Calo

Pandemic-related disruptions in primary care delayed important discussions between providers and parents about routine vaccinations. Conversations have become even more challenging since the COVID-19 pandemic due to increased vaccine hesitancy. This qualitative study explored changes in human papillomavirus (HPV) vaccine conversations within the context of the pandemic from the perspective of primary care team members (PCTMs). Twenty-five PCTMs serving children between 9 and 17 y old in Pennsylvania during the pandemic were conveniently sampled. PCTMs rated their confidence and agreement related to HPV vaccine conversations and pandemic impact. Semi-structured interview questions assessed changes in their HPV vaccine conversations throughout the pandemic. Open-ended questions inquired about PCTMs' thoughts on the COVID-19 pandemic and if or how it impacted HPV vaccination uptake in their practice. Data were collected from May to July 2024. Verbatim transcriptions were analyzed using both inductive and deductive approaches to thematic analysis. Participants were 44% pediatricians, 50% had ≥20 y experience, and 68% were White. Six themes emerged: (1) parents show a range of reactions about HPV vaccination; (2) disruptions in healthcare visits and heightened parental concerns impede vaccination; (3) PCTMs notice clear changes in vaccine acceptance rates; (4) reasons for vaccination refusal have not substantially changed as a result of the pandemic; (5) importance of interpersonal relationships with parents; and (6) PCTM burnout impacts conversations. The pandemic added challenges to HPV vaccine conversations with parents. Findings from this study can be used to refine existing communication approaches to improve HPV vaccine conversations in primary care.

{"title":"\"The big topic is COVID\": A qualitative study about changes in HPV vaccine conversations between parents and primary care team members throughout the COVID-19 pandemic.","authors":"Josheili Y Llavona-Ortiz, Lauren J Van Scoy, Benjamin Fogel, Casey Pinto, Jamelia Graham, William A Calo","doi":"10.1080/21645515.2025.2460844","DOIUrl":"https://doi.org/10.1080/21645515.2025.2460844","url":null,"abstract":"<p><p>Pandemic-related disruptions in primary care delayed important discussions between providers and parents about routine vaccinations. Conversations have become even more challenging since the COVID-19 pandemic due to increased vaccine hesitancy. This qualitative study explored changes in human papillomavirus (HPV) vaccine conversations within the context of the pandemic from the perspective of primary care team members (PCTMs). Twenty-five PCTMs serving children between 9 and 17 y old in Pennsylvania during the pandemic were conveniently sampled. PCTMs rated their confidence and agreement related to HPV vaccine conversations and pandemic impact. Semi-structured interview questions assessed changes in their HPV vaccine conversations throughout the pandemic. Open-ended questions inquired about PCTMs' thoughts on the COVID-19 pandemic and if or how it impacted HPV vaccination uptake in their practice. Data were collected from May to July 2024. Verbatim transcriptions were analyzed using both inductive and deductive approaches to thematic analysis. Participants were 44% pediatricians, 50% had ≥20 y experience, and 68% were White. Six themes emerged: (1) parents show a range of reactions about HPV vaccination; (2) disruptions in healthcare visits and heightened parental concerns impede vaccination; (3) PCTMs notice clear changes in vaccine acceptance rates; (4) reasons for vaccination refusal have not substantially changed as a result of the pandemic; (5) importance of interpersonal relationships with parents; and (6) PCTM burnout impacts conversations. The pandemic added challenges to HPV vaccine conversations with parents. Findings from this study can be used to refine existing communication approaches to improve HPV vaccine conversations in primary care.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2460844"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143366299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Profile of Chlamydia vaccine research: A bibliometric analysis. 衣原体疫苗研究概况:文献计量分析。
IF 4.1 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Pub Date : 2025-12-01 Epub Date: 2025-02-05 DOI: 10.1080/21645515.2025.2459459
Xuemei Wang, Qian Wang, Yidan Gao, Lijuan Jiang, Lingli Tang

Vaccination is the most effective measure to prevent Chlamydia infection. However, to date, no vaccine has successfully completed the rigorous clinical trial process and gained regulatory approval for use in clinical practice. Scholars have been working on a safe and effective Chlamydia vaccine. In order to better grasp, the global frontiers and development trends in this field, a comprehensive bibliometric analysis was carried out. A total of 234 publications closely regarding Chlamydia vaccines were culled from the Web of Science Core Collection database, and the bibliometric information was then extracted with CiteSpace and VOSviewer software. After measurement analysis, the most influential papers were identified in this area, including highly cited papers, references with strong citation burst, and high co-citated papers. Vaccine has published the most literature on Chlamydia vaccines. Only scholars from 39 countries/regions have been engaged in studying Chlamydia vaccines. The USA is the most prolific country and has the highest collaborative strength. The current research area has focused on protective immunity and immunopathological response. Major outer membrane protein (MOMP) is the most common target vaccine antigen. This study reveals the status of literature and highlights emerging trends in this field, which helps researchers seek insights into this area and serve as a reference guide for further investigations.

{"title":"Profile of <i>Chlamydia</i> vaccine research: A bibliometric analysis.","authors":"Xuemei Wang, Qian Wang, Yidan Gao, Lijuan Jiang, Lingli Tang","doi":"10.1080/21645515.2025.2459459","DOIUrl":"10.1080/21645515.2025.2459459","url":null,"abstract":"<p><p>Vaccination is the most effective measure to prevent <i>Chlamydia</i> infection. However, to date, no vaccine has successfully completed the rigorous clinical trial process and gained regulatory approval for use in clinical practice. Scholars have been working on a safe and effective <i>Chlamydia</i> vaccine. In order to better grasp, the global frontiers and development trends in this field, a comprehensive bibliometric analysis was carried out. A total of 234 publications closely regarding <i>Chlamydia</i> vaccines were culled from the Web of Science Core Collection database, and the bibliometric information was then extracted with CiteSpace and VOSviewer software. After measurement analysis, the most influential papers were identified in this area, including highly cited papers, references with strong citation burst, and high co-citated papers. <i>Vaccine</i> has published the most literature on <i>Chlamydia</i> vaccines. Only scholars from 39 countries/regions have been engaged in studying <i>Chlamydia</i> vaccines. The USA is the most prolific country and has the highest collaborative strength. The current research area has focused on protective immunity and immunopathological response. Major outer membrane protein (MOMP) is the most common target vaccine antigen. This study reveals the status of literature and highlights emerging trends in this field, which helps researchers seek insights into this area and serve as a reference guide for further investigations.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2459459"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11801346/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143191066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Influenza vaccination hesitancy and related factors among pregnant and breastfeeding women: A cross-sectional study. 孕妇和哺乳期妇女流感疫苗接种犹豫及其相关因素:一项横断面研究
IF 4.1 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Pub Date : 2025-12-01 Epub Date: 2025-01-14 DOI: 10.1080/21645515.2025.2450858
Dania Comparcini, Giancarlo Cicolini, Melania Totaro, Letizia Governatori, Francesco Pastore, Daniela Miniscalco, Maria Elena Flacco, Eustachio Cuscianna, Silvio Tafuri, Valentina Simonetti

Achieving safe influenza vaccination coverage among pregnant and breastfeeding women is a global health goal due to the potential risks of serious influenza for both mother and child. However, vaccine hesitancy remains a significant barrier to vaccination uptake. Since anxiety represents a determinant in vaccine decision-making, this study aimed to assess influenza vaccination hesitancy and anxiety levels in this population and to explore the association between women's characteristics, their reluctance, and anxiety levels. A multicentre, cross-sectional study was conducted between February and June 2022 using structured phone interviews to assess: (1) socio-demographics and clinical history; (2) anti-flu vaccination status, previous anti-flu vaccination, and Sars-CoV-2 infection history; (3) insights into influenza vaccination during pregnancy; (4) attitudes toward anti-flu vaccination, using the Vaccination Attitudes Examination (VAX) Scale; (5) anxiety levels, measured by the Self-Rating Anxiety Scale (SAS). Among the 387 participants, 22.8% were already vaccinated or expressed willingness to be vaccinated against influenza, and 54% had an anxiety disorder. While anxiety was not significantly associated with vaccine hesitancy, ongoing pregnancy emerged as an independent predictor of anxiety. Higher educational levels, ongoing pregnancy, already being vaccinated or willingness to get vaccinated, and being employed were associated with reduced vaccine hesitancy, while prior SARS-CoV-2 infection with increased hesitancy. Fear of unpredictable events and lack of healthcare professionals' recommendations emerged as reasons for vaccine reluctance. Given the low coverage rates, these findings highlight the need for health services to enhance vaccination efforts and provide clear recommendations to counter misinformation and ensure accurate vaccine safety information.

由于严重流感对母亲和儿童的潜在风险,在孕妇和哺乳期妇女中实现安全的流感疫苗接种覆盖率是一项全球卫生目标。然而,疫苗犹豫仍然是接种疫苗的一个重大障碍。由于焦虑是疫苗接种决策的一个决定因素,本研究旨在评估这一人群中流感疫苗接种犹豫和焦虑水平,并探讨女性特征、她们的不情愿和焦虑水平之间的关系。在2022年2月至6月期间进行了一项多中心横断面研究,采用结构化电话访谈来评估:(1)社会人口统计学和临床病史;(2)抗流感疫苗接种情况、既往抗流感疫苗接种情况、Sars-CoV-2感染史;(3)对孕期流感疫苗接种的认识;(4)疫苗接种态度调查(VAX)量表;(5)焦虑水平,采用焦虑自评量表(SAS)测量。在387名参与者中,22.8%的人已经接种了流感疫苗或表示愿意接种流感疫苗,54%的人患有焦虑症。虽然焦虑与疫苗犹豫没有显著关联,但持续妊娠是焦虑的独立预测因素。较高的教育水平、正在怀孕、已经接种疫苗或愿意接种疫苗以及有工作与疫苗犹豫减少有关,而先前的SARS-CoV-2感染与犹豫增加有关。对不可预测事件的恐惧和缺乏卫生保健专业人员的建议成为不愿接种疫苗的原因。鉴于覆盖率较低,这些调查结果强调卫生服务部门需要加强疫苗接种工作,并提供明确建议,以打击错误信息并确保准确的疫苗安全信息。
{"title":"Influenza vaccination hesitancy and related factors among pregnant and breastfeeding women: A cross-sectional study.","authors":"Dania Comparcini, Giancarlo Cicolini, Melania Totaro, Letizia Governatori, Francesco Pastore, Daniela Miniscalco, Maria Elena Flacco, Eustachio Cuscianna, Silvio Tafuri, Valentina Simonetti","doi":"10.1080/21645515.2025.2450858","DOIUrl":"10.1080/21645515.2025.2450858","url":null,"abstract":"<p><p>Achieving safe influenza vaccination coverage among pregnant and breastfeeding women is a global health goal due to the potential risks of serious influenza for both mother and child. However, vaccine hesitancy remains a significant barrier to vaccination uptake. Since anxiety represents a determinant in vaccine decision-making, this study aimed to assess influenza vaccination hesitancy and anxiety levels in this population and to explore the association between women's characteristics, their reluctance, and anxiety levels. A multicentre, cross-sectional study was conducted between February and June 2022 using structured phone interviews to assess: (1) socio-demographics and clinical history; (2) anti-flu vaccination status, previous anti-flu vaccination, and Sars-CoV-2 infection history; (3) insights into influenza vaccination during pregnancy; (4) attitudes toward anti-flu vaccination, using the Vaccination Attitudes Examination (VAX) Scale; (5) anxiety levels, measured by the Self-Rating Anxiety Scale (SAS). Among the 387 participants, 22.8% were already vaccinated or expressed willingness to be vaccinated against influenza, and 54% had an anxiety disorder. While anxiety was not significantly associated with vaccine hesitancy, ongoing pregnancy emerged as an independent predictor of anxiety. Higher educational levels, ongoing pregnancy, already being vaccinated or willingness to get vaccinated, and being employed were associated with reduced vaccine hesitancy, while prior SARS-CoV-2 infection with increased hesitancy. Fear of unpredictable events and lack of healthcare professionals' recommendations emerged as reasons for vaccine reluctance. Given the low coverage rates, these findings highlight the need for health services to enhance vaccination efforts and provide clear recommendations to counter misinformation and ensure accurate vaccine safety information.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2450858"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11740437/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142985146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Uptake and service preferences of human papillomavirus vaccination in men who have sex with men. 男男性行为者人乳头瘤病毒疫苗接种的吸收和服务偏好。
IF 4.1 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Pub Date : 2025-12-01 Epub Date: 2024-12-22 DOI: 10.1080/21645515.2024.2440956
Rui Zhang, Ngai Sze Wong, Sze Long Chung, Chi Keung Kwan, Tsz Ho Kwan, Shui Shan Lee

Human papillomavirus (HPV) vaccination could reduce HPV infection in men who have sex with men (MSM), but the published statistics on HPV vaccination uptake in MSM were scarce globally. This study estimated the uptake and profiled the service preferences of HPV vaccination of Chinese MSM in Hong Kong. Adult MSM were recruited through non-governmental organizations (NGOs) and online channels for completing an online baseline survey. Factors associated with self-reported history of HPV vaccination were identified using multivariable stepwise logistic regression model. Totally 701 Chinese MSM completed the online baseline survey, with the median age of 30 y (interquartile range [IQR] 26-35, range 18-67), and 23% of them had received HPV vaccination. More than half of vaccinated MSM (72%) rated convenient or very convenient for local HPV vaccination services. Among unvaccinated MSM, 50% considered high cost of HPV vaccine as the barrier of vaccination, 67% expressed willingness to pay below USD 128 per vaccine dose, and 65% preferred receiving vaccination in private clinics. MSM who had taken HIV pre-exposure prophylaxis (PrEP) (p < .001), had been tested for HPV (p = .018), and had (p = .005) multiple regular sex partners in the past 6 months were more likely to be vaccinated. The HPV vaccination uptake of Chinese MSM in Hong Kong remains low (23%), and high HPV vaccine cost is the main barrier. Preventive behaviors (HIV PrEP use and HPV testing) and high-risk sexual behavior (multiple regular sex partners) are potential targets for intervention to increase the uptake of HPV vaccination in MSM.

人乳头瘤病毒(HPV)疫苗接种可以减少男男性行为者(MSM)的HPV感染,但在全球范围内,已发表的关于MSM接种HPV疫苗的统计数据很少。本研究估计了香港华人男男性接触者的HPV疫苗接种情况,并分析了服务偏好。通过非政府组织和在线渠道招募成年男男性行为者完成在线基线调查。使用多变量逐步logistic回归模型确定与自我报告HPV疫苗接种史相关的因素。共有701名中国MSM完成了在线基线调查,中位年龄为30岁(四分位数范围[IQR] 26-35,范围18-67),其中23%的人接受了HPV疫苗接种。超过一半接种过疫苗的男男性行为者(72%)认为当地HPV疫苗接种服务方便或非常方便。在未接种疫苗的MSM中,50%的人认为HPV疫苗的高成本是接种疫苗的障碍,67%的人表示愿意支付每剂疫苗低于128美元的费用,65%的人更愿意在私人诊所接种疫苗。接受过HIV暴露前预防(PrEP) (p = 0.018)和在过去6个月内有多个性伴侣(p = 0.005)的男男性接触者更有可能接种疫苗。在香港,中国男男性接触者的HPV疫苗接种率仍然很低(23%),HPV疫苗的高成本是主要障碍。预防行为(使用HIV PrEP和HPV检测)和高危性行为(多个性伴侣)是增加男男性接触者HPV疫苗接种率的潜在干预目标。
{"title":"Uptake and service preferences of human papillomavirus vaccination in men who have sex with men.","authors":"Rui Zhang, Ngai Sze Wong, Sze Long Chung, Chi Keung Kwan, Tsz Ho Kwan, Shui Shan Lee","doi":"10.1080/21645515.2024.2440956","DOIUrl":"https://doi.org/10.1080/21645515.2024.2440956","url":null,"abstract":"<p><p>Human papillomavirus (HPV) vaccination could reduce HPV infection in men who have sex with men (MSM), but the published statistics on HPV vaccination uptake in MSM were scarce globally. This study estimated the uptake and profiled the service preferences of HPV vaccination of Chinese MSM in Hong Kong. Adult MSM were recruited through non-governmental organizations (NGOs) and online channels for completing an online baseline survey. Factors associated with self-reported history of HPV vaccination were identified using multivariable stepwise logistic regression model. Totally 701 Chinese MSM completed the online baseline survey, with the median age of 30 y (interquartile range [IQR] 26-35, range 18-67), and 23% of them had received HPV vaccination. More than half of vaccinated MSM (72%) rated convenient or very convenient for local HPV vaccination services. Among unvaccinated MSM, 50% considered high cost of HPV vaccine as the barrier of vaccination, 67% expressed willingness to pay below USD 128 per vaccine dose, and 65% preferred receiving vaccination in private clinics. MSM who had taken HIV pre-exposure prophylaxis (PrEP) (<i>p</i> < .001), had been tested for HPV (<i>p</i> = .018), and had (<i>p</i> = .005) multiple regular sex partners in the past 6 months were more likely to be vaccinated. The HPV vaccination uptake of Chinese MSM in Hong Kong remains low (23%), and high HPV vaccine cost is the main barrier. Preventive behaviors (HIV PrEP use and HPV testing) and high-risk sexual behavior (multiple regular sex partners) are potential targets for intervention to increase the uptake of HPV vaccination in MSM.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2440956"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142877184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Influenza vaccine effectiveness against medically-attended influenza infection in 2023/24 season in Hangzhou, China. 中国杭州 2023/24 季度流感疫苗预防就诊流感感染的有效性。
IF 4.1 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Pub Date : 2025-12-01 Epub Date: 2024-12-20 DOI: 10.1080/21645515.2024.2435156
Hao Lei, Beidi Niu, Zhou Sun, Yaojing Wang, Xinren Che, Shengqiang Du, Yan Liu, Ke Zhang, Shi Zhao, Shigui Yang, Zhe Wang, Gang Zhao

From 2020, influenza viruses circulation was largely affected by the global coronavirus disease (COVID-19) pandemic, notably leading to the extinction of the B/Yamagata lineage and raising questions about the relevance of the quadrivalent influenza vaccine, which includes this lineage. Evaluating vaccine effectiveness (VE) against influenza infections is important to inform future vaccine programs. A test-negative case-control study was conducted in five tertiary hospitals in Hangzhou, the capital city of Zhejiang province, China, enrolling medically-attended patients aged >6 months who presented with influenza-like illness (ILI) from October 1, 2023, to March 31, 2024. The VE was estimated using multivariate logistic regression models adjusted for sex, age, influenza detection methods, and influenza testing timing. Of the 157,291 medically-attended ILI participants enrolled 56,704 (36%) tested positive for influenza. Adjusted overall VE against any medically-attended influenza infection was 48% (95% Confidence interval [CI]: 46%-51%). The overall VE of the trivalent inactivated influenza vaccine (IIV3) was 59% (95% CI: 50%-66%), followed by the trivalent live attenuated vaccine (LAIV3) (VE = 53%, 95% CI: 42%-62%) and quadrivalent inactivated influenza vaccine (IIV4) (VE = 47%, 95% CI: 45%-50%). IIV3 provided even better protection against medically-attended influenza B infection than IIV4 (VE = 87%, 95% CI: 81%-92% for IIV3 versus VE = 53%, 95% CI: 50%-57% for IIV4). In the 2023/24 season in Hangzhou, China, the influenza vaccine offered moderate protection during a major epidemic. The results supported the World Health Organization recommendation to exclude the B/Yamagata lineage antigen in quadrivalent influenza vaccines in 2023.

从2020年开始,流感病毒的传播在很大程度上受到全球冠状病毒病(COVID-19)大流行的影响,特别是导致B/Yamagata谱系的灭绝,并对包括该谱系在内的四价流感疫苗的相关性提出了质疑。评估疫苗对流感感染的有效性(VE)对未来的疫苗规划具有重要意义。在中国浙江省省会杭州市的五家三级医院进行了一项检测阴性病例对照研究,纳入了2023年10月1日至2024年3月31日期间出现流感样疾病(ILI)的年龄在100至6个月的住院患者。使用多变量logistic回归模型对性别、年龄、流感检测方法和流感检测时间进行校正,估计VE。在157,291名接受医疗护理的ILI参与者中,56,704人(36%)的流感检测呈阳性。针对任何医疗护理流感感染的调整后总体VE为48%(95%可信区间[CI]: 46%-51%)。三价流感灭活疫苗(IIV3)的总体VE为59% (95% CI: 50%-66%),其次是三价减毒活疫苗(LAIV3) (VE = 53%, 95% CI: 42%-62%)和四价流感灭活疫苗(IIV4) (VE = 47%, 95% CI: 45%-50%)。与IIV4相比,IIV3对医护人员感染乙型流感提供更好的保护(VE = 87%, 95% CI: IIV3为81%-92%,而IIV4为53%,95% CI: 50%-57%)。在中国杭州的2023/24流感季节,流感疫苗在重大流行病期间提供了中等保护。该结果支持了世界卫生组织关于在2023年在四价流感疫苗中排除B/山形谱系抗原的建议。
{"title":"Influenza vaccine effectiveness against medically-attended influenza infection in 2023/24 season in Hangzhou, China.","authors":"Hao Lei, Beidi Niu, Zhou Sun, Yaojing Wang, Xinren Che, Shengqiang Du, Yan Liu, Ke Zhang, Shi Zhao, Shigui Yang, Zhe Wang, Gang Zhao","doi":"10.1080/21645515.2024.2435156","DOIUrl":"https://doi.org/10.1080/21645515.2024.2435156","url":null,"abstract":"<p><p>From 2020, influenza viruses circulation was largely affected by the global coronavirus disease (COVID-19) pandemic, notably leading to the extinction of the B/Yamagata lineage and raising questions about the relevance of the quadrivalent influenza vaccine, which includes this lineage. Evaluating vaccine effectiveness (VE) against influenza infections is important to inform future vaccine programs. A test-negative case-control study was conducted in five tertiary hospitals in Hangzhou, the capital city of Zhejiang province, China, enrolling medically-attended patients aged >6 months who presented with influenza-like illness (ILI) from October 1, 2023, to March 31, 2024. The VE was estimated using multivariate logistic regression models adjusted for sex, age, influenza detection methods, and influenza testing timing. Of the 157,291 medically-attended ILI participants enrolled 56,704 (36%) tested positive for influenza. Adjusted overall VE against any medically-attended influenza infection was 48% (95% Confidence interval [CI]: 46%-51%). The overall VE of the trivalent inactivated influenza vaccine (IIV3) was 59% (95% CI: 50%-66%), followed by the trivalent live attenuated vaccine (LAIV3) (VE = 53%, 95% CI: 42%-62%) and quadrivalent inactivated influenza vaccine (IIV4) (VE = 47%, 95% CI: 45%-50%). IIV3 provided even better protection against medically-attended influenza B infection than IIV4 (VE = 87%, 95% CI: 81%-92% for IIV3 versus VE = 53%, 95% CI: 50%-57% for IIV4). In the 2023/24 season in Hangzhou, China, the influenza vaccine offered moderate protection during a major epidemic. The results supported the World Health Organization recommendation to exclude the B/Yamagata lineage antigen in quadrivalent influenza vaccines in 2023.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2435156"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142865663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From PD-1/PD-L1 to tertiary lymphoid structures: Paving the way for precision immunotherapy in cholangiocarcinoma treatment. 从PD-1/PD-L1到三级淋巴组织:为胆管癌的精准免疫治疗铺平道路
IF 4.1 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Pub Date : 2025-12-01 Epub Date: 2025-01-06 DOI: 10.1080/21645515.2024.2444697
Fang-Ju Huang, Ye-Ying Fang, Jia-Ying Wen, Jian-Jun Li, Qian Lin, Qin-Yan Su, Yi-Yang Chen, Lei Wang, Jian-Jia Zeng, Bang-Teng Chi, Rong-Quan He, Di-Yuan Qin, Li-Hua Yang, Gang Chen

Cholangiocarcinoma (CCA) is a highly malignant hepatobiliary tumor characterized by limited treatment options and poor prognosis. The recent rise of immunotherapy has significantly influenced research in this field. This study presents a bibliometric analysis of 416 articles retrieved from the WOSCC, Wan fang Data, CNKI and VIP databases, spanning contributions from 32 countries, 589 institutions and 3,200 authors. The analysis identified "PD-L1," "PD-1" and "pembrolizumab" as central research foci, while "immune checkpoint inhibitors," "tumor immune microenvironment," "tertiary lymphoid structures" and "durvalumab" emerged as key areas of interest. These findings emphasize the pivotal role of immunotherapy in improving survival outcomes for CCA, and they highlight the significance of tertiary lymphoid structures within the tumor microenvironment as a promising target for future research. This study offers a strategic overview of the evolving landscape of CCA immunotherapy, providing valuable insights to guide future scientific endeavors in this domain.

胆管癌(CCA)是一种高度恶性的肝胆肿瘤,其特点是治疗方案有限,预后差。近年来免疫疗法的兴起对这一领域的研究产生了重大影响。本研究采用文献计量学方法分析了从世界文献中心、万方数据、中国知网和VIP数据库中检索到的416篇论文,涵盖32个国家、589个机构和3200位作者。该分析确定“PD-L1”,“PD-1”和“pembrolizumab”为中心研究焦点,而“免疫检查点抑制剂”,“肿瘤免疫微环境”,“三级淋巴样结构”和“durvalumab”成为关键研究领域。这些发现强调了免疫治疗在改善CCA生存结果中的关键作用,并强调了肿瘤微环境中的三级淋巴结构作为未来研究的一个有希望的目标的重要性。本研究为CCA免疫疗法的发展前景提供了一个战略概述,为指导该领域未来的科学努力提供了有价值的见解。
{"title":"From PD-1/PD-L1 to tertiary lymphoid structures: Paving the way for precision immunotherapy in cholangiocarcinoma treatment.","authors":"Fang-Ju Huang, Ye-Ying Fang, Jia-Ying Wen, Jian-Jun Li, Qian Lin, Qin-Yan Su, Yi-Yang Chen, Lei Wang, Jian-Jia Zeng, Bang-Teng Chi, Rong-Quan He, Di-Yuan Qin, Li-Hua Yang, Gang Chen","doi":"10.1080/21645515.2024.2444697","DOIUrl":"https://doi.org/10.1080/21645515.2024.2444697","url":null,"abstract":"<p><p>Cholangiocarcinoma (CCA) is a highly malignant hepatobiliary tumor characterized by limited treatment options and poor prognosis. The recent rise of immunotherapy has significantly influenced research in this field. This study presents a bibliometric analysis of 416 articles retrieved from the WOSCC, Wan fang Data, CNKI and VIP databases, spanning contributions from 32 countries, 589 institutions and 3,200 authors. The analysis identified \"PD-L1,\" \"PD-1\" and \"pembrolizumab\" as central research foci, while \"immune checkpoint inhibitors,\" \"tumor immune microenvironment,\" \"tertiary lymphoid structures\" and \"durvalumab\" emerged as key areas of interest. These findings emphasize the pivotal role of immunotherapy in improving survival outcomes for CCA, and they highlight the significance of tertiary lymphoid structures within the tumor microenvironment as a promising target for future research. This study offers a strategic overview of the evolving landscape of CCA immunotherapy, providing valuable insights to guide future scientific endeavors in this domain.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2444697"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142933382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficiency enhancement in main path extraction in mRNA vaccine field: A novel approach leveraging intermediate patents, with shielding origin and terminus patent edges. 提高mRNA疫苗领域主路径提取效率:一种利用中间专利、屏蔽起始和末端专利边缘的新方法。
IF 4.1 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Pub Date : 2025-12-01 Epub Date: 2025-01-22 DOI: 10.1080/21645515.2025.2454078
Ting Zhang, Zhongquan Jian, Juan Chen, Dongzi Xu, Xiaoyi Yang, Yan Lu, Shu Yan, Lizi Pan, Qingqiang Wu, Zhaolian Ouyang

mRNA vaccines offer groundbreaking technological advantages and broad application potential. Their rapid advancement, particularly during the COVID-19 pandemic, is the result of decades of research and numerous technological breakthroughs. These discoveries build upon each other, forming dense, interconnected networks of progress. Studying the technological development paths of mRNA vaccines is therefore essential. Main path analysis (MPA) is particularly effective for mapping out development trajectories within complex and interconnected networks, which serves as a powerful tool for identifying key nodes and innovations. This study introduces a novel approach to extracting main paths from a patent citation network in the mRNA vaccine field. Initially, we shielded edges connecting the origin and terminus patents. Subsequently, we extracted the main paths from intermediate patents, and then, we reintegrated the edges connecting the origin and terminus patents based on the citation relationships, resulting in a comprehensive extraction of the main paths. The research findings indicate a consistency among the global main paths, global key-route main paths, local forward main paths, and local key-route main paths within the mRNA vaccine field. The patents on the main paths predominantly focus on nucleic acid modifications and delivery systems. The local backward main paths identify a greater number of patents, especially those related to litigation, offering a richer and more diverse set of technological insights. This study significantly advances the methodology of MPA, with the innovative shielding technique offering a fresh perspective for navigating complex networks and providing a deeper understanding of technological development in the mRNA vaccine domain.

mRNA疫苗具有突破性的技术优势和广泛的应用潜力。它们的迅速发展,特别是在2019冠状病毒病大流行期间,是数十年研究和众多技术突破的结果。这些发现相互依存,形成了密集的、相互联系的进步网络。因此,研究mRNA疫苗的技术发展路径至关重要。主路径分析对于在复杂和相互关联的网络中规划发展轨迹特别有效,是确定关键节点和创新的有力工具。本研究介绍了一种从mRNA疫苗领域专利引文网络中提取主要路径的新方法。最初,我们屏蔽了连接原点和终点专利的边缘。随后,我们从中间专利中提取主要路径,然后根据引文关系重新整合连接起始专利和终止专利的边缘,从而得到全面的主要路径提取。研究结果表明,mRNA疫苗领域的全局主路径、全局关键路径主路径、局部转发主路径和局部关键路径主路径具有一致性。主要途径的专利主要集中在核酸修饰和递送系统上。当地落后的主要路径确定了更多的专利,特别是那些与诉讼有关的专利,提供了更丰富、更多样化的技术见解。这项研究显著推进了MPA的方法学,创新的屏蔽技术为导航复杂网络提供了新的视角,并对mRNA疫苗领域的技术发展提供了更深入的了解。
{"title":"Efficiency enhancement in main path extraction in mRNA vaccine field: A novel approach leveraging intermediate patents, with shielding origin and terminus patent edges.","authors":"Ting Zhang, Zhongquan Jian, Juan Chen, Dongzi Xu, Xiaoyi Yang, Yan Lu, Shu Yan, Lizi Pan, Qingqiang Wu, Zhaolian Ouyang","doi":"10.1080/21645515.2025.2454078","DOIUrl":"https://doi.org/10.1080/21645515.2025.2454078","url":null,"abstract":"<p><p>mRNA vaccines offer groundbreaking technological advantages and broad application potential. Their rapid advancement, particularly during the COVID-19 pandemic, is the result of decades of research and numerous technological breakthroughs. These discoveries build upon each other, forming dense, interconnected networks of progress. Studying the technological development paths of mRNA vaccines is therefore essential. Main path analysis (MPA) is particularly effective for mapping out development trajectories within complex and interconnected networks, which serves as a powerful tool for identifying key nodes and innovations. This study introduces a novel approach to extracting main paths from a patent citation network in the mRNA vaccine field. Initially, we shielded edges connecting the origin and terminus patents. Subsequently, we extracted the main paths from intermediate patents, and then, we reintegrated the edges connecting the origin and terminus patents based on the citation relationships, resulting in a comprehensive extraction of the main paths. The research findings indicate a consistency among the global main paths, global key-route main paths, local forward main paths, and local key-route main paths within the mRNA vaccine field. The patents on the main paths predominantly focus on nucleic acid modifications and delivery systems. The local backward main paths identify a greater number of patents, especially those related to litigation, offering a richer and more diverse set of technological insights. This study significantly advances the methodology of MPA, with the innovative shielding technique offering a fresh perspective for navigating complex networks and providing a deeper understanding of technological development in the mRNA vaccine domain.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2454078"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143014646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Human Vaccines & Immunotherapeutics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1